Impact News +++ Will Applied Digital′s Second Campus Unlock the Next Leg of Growth? (Zacks) +++ APPLIED DIGITAL Aktie +3,93%

BIOVAXYS Aktie

>BIOVAXYS Performance

1 Woche: -1,4%

1 Monat: +2,3%

3 Monate: 0%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>BIOVAXYS Aktie

Name:

BIOVAXYS TECHNOLOGY CORP.

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA09076M2004 / A41C58

Symbol/ Ticker:

5LB0 (Frankfurt)

Kürzel:

FRA:5LB0, ETR:5LB0, 5LB0:GR

Index:

Webseite:

https://www.biovaxys.com/

Profil:

BioVaxys Technology Corp., a clinical-stage biotec..
>Volltext..

Marktkapitalisierung:

5.03 Mio. EUR

Unternehmenswert:

5.11 Mio. EUR

Umsatz:

EBITDA:

-3.07 Mio. EUR

Nettogewinn:

-3.79 Mio. EUR

Gewinn je Aktie:

-0.14 EUR

Schulden:

0.08 Mio. EUR

Liquide Mittel:

Operativer Cashflow:

-1.86 Mio. EUR

Bargeldquote:

Umsatzwachstum:

Gewinnwachstum:

-17.07%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

BIOVAXYS

Letzte Datenerhebung:

22.11.25

>BIOVAXYS Kennzahlen

Aktien/ Unternehmen:

Aktien: 29.15 Mio. St.

Frei handelbar: 88.15%

Leerverk. Aktien: -

Rückkaufquote: -31.56%

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Neutral

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -318.42%

Eigenkaprendite: -

>BIOVAXYS Peer Group

Es sind 182 Aktien bekannt.

>BIOVAXYS Chart & Kurs - Stuttgart

>BIOVAXYS News

19.11.25 - 21:45

BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement (The Newswire)

VANCOUVER, BC, November 19, 2025 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or the “Company”) announces that it has closed its previously announced non-brokered private placement financing (the “Offering”) of 11,311,676 units of the Company (the “Units”) at an issue price of $0.17 per Unit for aggregate gross proceeds of $1,922,984.92. Each Unit consists of one common share of the Company (“Share”) and one common share purchase warrant (“Warrant”), whereby each Warrant will entitle the holder thereof to acquire one additional Share at an exercise price of $0.40 for a period of 24 months from the date of issuance. The gross proceeds from the Offering are intended to be used to drive more organic pipeline growth by (1) pursuing multiple licensing opportunities and research collaborations with DPX where the Company's platform solutions can address specific needs or gaps, making the Company an attractive 'go-to' partner for targeted im...

30.10.25 - 21:57	BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M (PR Newswire)
	// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 30, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces an increase to its non-brokered private placement......

28.10.25 - 12:03	BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES (PR Newswire)
	// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 28, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces the conversion of outstanding......

22.10.25 - 09:48	BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES (PR Newswire)
	NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC, Oct. 22, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces the conversion of outstanding unsecured......

21.10.25 - 01:42	BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS (PR Newswire)
	// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 20, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces the conversion of outstanding......

08.10.25 - 14:03	BIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORS (PR Newswire)
	VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce that James Tartaglia, PhD, a former top R&D and commercial development executive with Sanofi Vaccines, has been appointed to the......

07.10.25 - 23:33	BIOVAXYS ANNOUNCES LIFE OFFERING (PR Newswire)
	// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it is undertaking a non-brokered private......

29.09.25 - 14:03	BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA") (PR Newswire)
	The APA Formalized the February 2024 BioVaxys Acquisition of the Former IMV Inc. Assets VANCOUVER, BC, Sept. 29, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce today that the Company and Horizon Technology Finance......

10.09.25 - 17:36	XFRA: ISIN Change (XETRA)
	Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen CA09076M1014 BioVaxys Technology Corp. 10.09.2025 CA09076M2004 BioVaxys Technology Corp. 11.09.2025 Tausch 10:1...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Jugend ist ein Rosenkranz, das Alter ist ein Dornenkranz. - Talmud

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram